

## Novavax Investor Relations

Novavax today announced that Switzerland's Federal Office of Public Health (FOPH) has recommended Nuvaxovid™ (NVX-CoV2373) as a heterologous and homologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 in adults aged 18 and older. The FOPH now recommends use of Nuvaxovid as an adult booster regardless of previous vaccine history as part of its autumn 2022 COVID-19 vaccine booster campaign.

The recommendation followed presentation of data describing the durability and breadth of immune response following heterologous and homologous boosting. This included data demonstrating Nuvaxovid can induce a functional immune response against currently circulating Omicron subvariants and that the immune response to these subvariants became more potent with subsequent boosting.

The recommendation for Novavax' protein-based vaccine follows the expanded temporary authorization of Nuvaxovid as a heterologous and homologous booster dose for adults aged 18 and older in [September 2022](#) from Swissmedic, the Swiss Agency for Therapeutic Products.

Nuvaxovid is also available for use in the [European Union](#), [Japan](#), [Australia](#), [New Zealand](#), and [Israel](#) as a booster and is actively under review in other markets. In addition, Novavax has ongoing trials to further explore Nuvaxovid's efficacy and safety as a booster.

### **Trade Name in the U.S.**

The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration.

---

<https://ir.novavax.com/Switzerlands-Federal-Office-of-Public-Health-Recommends-Novavax-Nuvaxovid-TM-COVID-19-Vaccine-as-a-Booster-in-Adults-Aged-18-and-Older>